Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven A Feldman

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Blood|September 24, 2013
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantationJames N Kochenderfer, Mark E Dudley, Robert O Carpenter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2022
Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous LymphocytesNikolaos Zacharakis, Lutfi M Huq, Samantha J Seitter, et al.
Nature Medicine|September 13, 2022
Post-infusion CAR T<sub>Reg</sub> cells identify patients resistant to CD19-CAR therapyZinaida Good, Jay Y Spiegel, Bita Sahaf, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 5, 2013
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapyRichard A Morgan, Nachimuthu Chinnasamy, Daniel Abate-Daga, et al.
Blood|January 29, 2021
CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphomaJohn H Baird, Matthew J Frank, Juliana Craig, et al.
Leukemia|March 16, 2024
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b resultsLiora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, et al.
Immunity|March 10, 2021
Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discoveryShin-Heng Chiou, Diane Tseng, Alexandre Reuben, et al.
Nature|February 7, 2022
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomasRobbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Nature|November 13, 2024
Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Blood|September 24, 2013
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantationJames N Kochenderfer, Mark E Dudley, Robert O Carpenter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2022
Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous LymphocytesNikolaos Zacharakis, Lutfi M Huq, Samantha J Seitter, et al.
Nature Medicine|September 13, 2022
Post-infusion CAR T<sub>Reg</sub> cells identify patients resistant to CD19-CAR therapyZinaida Good, Jay Y Spiegel, Bita Sahaf, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 5, 2013
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapyRichard A Morgan, Nachimuthu Chinnasamy, Daniel Abate-Daga, et al.
Blood|January 29, 2021
CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphomaJohn H Baird, Matthew J Frank, Juliana Craig, et al.
Leukemia|March 16, 2024
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b resultsLiora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, et al.
Immunity|March 10, 2021
Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discoveryShin-Heng Chiou, Diane Tseng, Alexandre Reuben, et al.
Nature|February 7, 2022
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomasRobbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Nature|November 13, 2024
Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Pageof 7